PUBLIC DISCLOSURE & CLARIFICATION

BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.

CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.

Recombinant Bacillus halodurans oligosaccharide reducing-end xylanase 8A

Inquiry

Cat. No.: X23-08-YM323

Recombinant Bacillus halodurans oligosaccharide reducing-end xylanase 8A

Synonym: BhRex8A; Beta-D-xylopyranosyl-(1->4)-beta-D-xylopyranose reducing-end xylanase

Enzyme Commission Number: 3.2.1.156

Product Size

1 mg; 2 mg; 3 mg; 6 mg

Price

Datasheet

MSDS

Properties

Description

Recombinant Bacillus halodurans oligosaccharide reducing-end xylanase 8A produced by Escherichia coli, involves the hydrolysis of 1-4-β-xylose residues specifically from the reducing end of oligosaccharides.

Expression System

Escherichia coli

Species

Bacillus halodurans

Concentration

1 mg/mL

Form

Liquid

Purity

≥90%, determined by SDS-PAGE.

Activity

Oligosaccharide reducing-end xylanases

Buffer

35 mM NaHepes buffer (pH 7.5), 750 mM NaCl, 200 mM imidazole, 3.5 mM CaCl₂, and 25% (v/v) glycerol

Applications

Recombinant Bacillus halodurans oligosaccharide reducing-end xylanase 8A can be used for glycobiology research. It has the ability to hydrolyze xylooligosaccharides.

Publications

Publications (0)

Publications

Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

GalNAc-L96 intermediate, T1 (Cat#: X24-11-YM010) GalNAc-L96 intermediate, T2 (Cat#: X24-11-YM011) GalNAc-L96 intermediate, T3 (Cat#: X24-11-YM012) GalNAc-L96 intermediate, T4-Amine (Cat#: X24-11-YM014) Tri-GalNAc(OAc)3 Cbz (Cat#: X24-11-YM015) Tri-GalNAc(OAc)3 (Cat#: X24-11-YM016) Tri-GalNAc(OAc)3 TFA (Cat#: X24-11-YM017) GalNAc-L96-OH (Cat#: X24-11-YM018) GalNAc-L96-TEA (Cat#: X24-11-YM019)

Neu5Gcα(2-6)N-Glycan (Cat#: X23-03-YW036) A2G2 N-Glycan (Cat#: X23-03-YW037) A2G2S2 N-Glycan (Cat#: X23-03-YW038) A2 N-Glycan (Cat#: X23-03-YW039) A2[6]G1 N-Glycan (Cat#: X23-03-YW040) M3 N-Glycan (Cat#: X23-03-YW041) A2[3]G2S1 N-Glycan (Cat#: X23-03-YW042)

Core 2 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW178) Core 2 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW179) Core 3 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW180) Core 3 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW181) Core 4 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW182) T antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW192) T antigen O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW193) Tn antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW194)

Blood group A trisaccharide (Cat#: XCO0060Q) Blood group B trisaccharide (Cat#: XCO0068Q) Blood group H disaccharide (Cat#: XCO0074Q) Lewis A trisaccharide (Cat#: XCO0079Q) 3'-Sulfated lewis A (Cat#: XCO0080Q) Lewis B tetrasaccharide (Cat#: XCO0083Q) Lewis X trisaccharide (Cat#: XCO0085Q) Lewis Y tetrasaccharide (Cat#: XCO0088Q)

Lacto-N-biose (Cat#: XCO0089Q) 2'-Fucosyllactose (Cat#: XCO0091Q) 3-Fucosyllactose (Cat#: XCO0092Q) Lactodifucotetraose (Cat#: XCO0093Q) Lacto-N-triose I (Cat#: XCO0094Q) 3'-Sialyllactose sodium salt (Cat#: XCO0096Q) 6'-Sialyllactose sodium salt (Cat#: XCO0098Q) 3'-Sialyl-3-fucosyllactose (Cat#: XCO0100Q)

Heparin amine, MW 27 kDa (Cat#: X22-09-ZQ478) FITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ480) TRITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ481) Biotin-heparin-FITC, MW 18 kDa (Cat#: X22-09-ZQ482) Chondroitin sulfate (dp4) (Cat#: X22-11-ZQ598) Dermatan sulfate (dp12) (Cat#: X22-11-ZQ611) Heparin disaccharide I-A (Cat#: X22-11-ZQ662) Chondroitine sulfate (Cat#: X23-04-XQ1118)

GalNAcβ(1-4)GlcNAcβ-Sp3-Biotin (Cat#: X22-12-ZQ005) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-Biotin (Cat#: X22-12-ZQ006) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-FITC (Cat#: X22-12-ZQ007) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA (Cat#: X22-12-ZQ008) Glcβ(1-4)GalNAcα-Sp3-Biotin (Cat#: X22-12-ZQ037) Glcβ(1-4)GalNAcα-Sp3-PAA-Biotin (Cat#: X22-12-ZQ038) Glcβ(1-4)GalNAcα-Sp3-PAA-FITC (Cat#: X22-12-ZQ039) Glcβ(1-4)GalNAcα-Sp3-PAA (Cat#: X22-12-ZQ040)

GlcCer (d18:1/8:0) (Cat#: X23-11-ZQ101) GalCer (d18:1/16:0) (Cat#: X23-11-ZQ112) LacCer (d18:1/8:0) (Cat#: X23-11-ZQ118) Lc3Cer (d18:1/8:0) (Cat#: X23-11-ZQ131) Lc4Cer (d18:1/12:0) (Cat#: X23-11-ZQ146) Sialyl-Lc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ162) Lewis a Cer (d18:1/16:0) (Cat#: X23-11-ZQ175) nLc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ190)

Methyl-γ-cyclodextrin (DS 12) (Cat#: X23-11-YM119) Carboxymethyl-ɑ-cyclodextrin sodium salt (Cat#: X23-11-B003) Carboxymethyl-γ-cyclodextrin sodium salt (Cat#: X23-11-B004) Succinyl-ɑ-cyclodextrin (Cat#: X23-11-B005) Succinyl-γ-cyclodextrin (Cat#: X23-11-B006) ɑ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B007) β-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B008) γ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B009)

Lysine-dextran, MW 4 kDa (Cat#: X22-09-ZQ273) Phenyl-dextran, MW 150 kDa (Cat#: X22-09-ZQ279) FITC-Q-dextran, MW 10 kDa (Cat#: X22-09-ZQ280) FITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ283) TRITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ287) FITC-dextran sulfate, MW 10 kDa (Cat#: X22-09-ZQ291) Dextran amine, MW 20 kDa (Cat#: X22-09-ZQ377) TRITC-dextran, MW 40 kDa (Cat#: X22-09-ZQ383) Biotin-dextran-FITC, MW 20 kDa (Cat#: X22-09-ZQ389)

Online Inquiry

About Us

CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.

Important Links

Contact Us

For research and manufacturing partners only. Not intended for (direct) human or veterinary use.